Empagliflozin + Linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also prescribed to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Empalina 25/5 Tablet is a combination of Empagliflozin and Linagliptin, used to manage type II diabetes mellitus among adult patients when conventional methods like diet, exercise, and other medications are not sufficient for adequate sugar control. It is also used as adjunct therapy in patients with diabetes and heart problems.
Follow proper hygiene and regular foot care as instructed by your doctor while taking Empalina 25/5 Tablet. Regularly monitor your blood glucose levels as instructed by your doctor.
Inform your doctor if you have any liver or kidney problems, or if you have been severely dehydrated due to excessive vomiting or diarrhea recently. Empalina 25/5 Tablet is not recommended for use in patients with Type I diabetes, alcoholism, or diabetic ketoacidosis.
Alcohol consumption while taking Empalina 25/5 Tablet may heighten the risk of adverse effects. It's advisable to avoid alcohol while on this medication, and consulting a doctor for personalized advice is prudent.
The potential effects of Empalina 25/5 Tablet on an unborn baby are not well understood, so it's generally advised to avoid using this medication during pregnancy unless deemed necessary by a doctor.
It's unclear whether Empalina 25/5 Tablet passes into breast milk, so caution is advised. Consulting a healthcare professional is recommended before using this medication while breastfeeding.
Avoid performing activities that require mental alertness, such as driving vehicles or operating machines, if you experience blurred vision or dizziness during treatment with this medicine.
For individuals with significant kidney issues, using Empalina 25/5 Tablet requires caution. Consulting a healthcare provider before starting this medication is crucial for proper guidance.
Severe liver problems contraindicate the use of Empalina 25/5 Tablet. Individuals with such conditions should consult their doctor before considering this medication.
Empagliflozin inhibits the sodium-glucose co-transporter 2 (SGLT2), reducing renal reabsorption of glucose and increasing urinary glucose excretion. Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing the concentrations of active incretin hormones, stimulating insulin release, and decreasing glucagon levels.
Common side effects include urinary tract infection, stuffy or runny nose, sore throat, and upper respiratory tract infection.
Do not miss a dose of Empalina 25/5 Tablet. If you do miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, then skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for the missed one.
Do not take more than the prescribed dose of Empalina 25/5 Tablet. If you suspect an overdose, seek emergency medical treatment immediately.
Empagliflozin works by inhibiting the action of the sodium-glucose co-transporter 2 (SGLT2), which is primarily responsible for reabsorbing glucose from the glomerular filtrate back into the bloodstream in the kidneys. By blocking SGLT2, empagliflozin reduces the renal reabsorption of filtered glucose, thereby lowering the renal threshold for glucose and increasing the excretion of glucose in the urine.
On the other hand, linagliptin functions as an inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, linagliptin raises the concentrations of active incretin hormones, which then stimulate the release of insulin from pancreatic beta cells in a glucose-dependent manner. Additionally, linagliptin reduces the levels of glucagon, another pancreatic hormone involved in regulating blood glucose levels. This dual action helps to improve glucose control by increasing insulin secretion and decreasing glucagon release, ultimately leading to a reduction in hepatic glucose production and improved glucose homeostasis.
The recommended dose is 10 mg empagliflozin and 5 mg linagliptin once daily, taken in the morning, with or without food. It may be increased to 25 mg empagliflozin and 5 mg linagliptin once daily based on clinical response.
Type 2 diabetes is indeed a chronic condition that affects how the body metabolizes sugar (glucose), a vital source of energy. When someone has type 2 diabetes, their body either resists the effects of insulin — a hormone that regulates the movement of sugar into your cells — or doesn't produce enough insulin to maintain normal glucose levels.
This type of diabetes is often associated with lifestyle factors such as obesity, physical inactivity, and poor dietary habits, although genetic and environmental factors also play a role.
Common symptoms of type 2 diabetes include:
While weight gain is common in individuals with type 2 diabetes due to insulin resistance and metabolic imbalances, some people may experience weight loss, especially if the condition is poorly managed or if diabetes-related complications arise.
Complications associated with type 2 diabetes can affect various organs and systems in the body. These may include:
Early detection, proper management through medication, lifestyle modifications (such as healthy eating, regular exercise, and weight management), and regular medical check-ups are essential for effectively managing type 2 diabetes and reducing the risk of complications.
Before taking Empalina 25/5 Tablet, inform your doctor if you are taking other medicines used to manage diabetes, epilepsy, hypertension, mental illness, or tuberculosis, as interactions may occur.
Hypersensitivity to the active substance or to any of the excipients.
Empalina 25/5 Tablet is not recommended during pregnancy due to potential fetal risk, especially in the second and third trimesters. It is also not recommended while breastfeeding.
Pancreatitis, ketoacidosis, volume depletion, urosepsis, pyelonephritis, hypoglycemia, necrotizing fasciitis of the perineum, genital mycotic infections, hypersensitivity reactions, arthralgia, bullous pemphigoid, and heart failure are some of the precautions and warnings associated with Empalina 25/5 Tablet.
Keep Empalina Empalina 25/5 Tablet below 30°C temperature, away from light & moisture, and out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.